Filing Flows › Health Care › Globus Medical (GMED)
Globus Medical (GMED) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Globus Medical (GMED) Q3 2026 earnings results →
Q3 2026 Revenue down 1% year over year to $764M · 18¢ of every $1 of revenue kept as net profit · operating margin 23.2%
Globus Medical made $764M in Q3 2026 (-0.7% Y/Y): Musculoskeletal Solutions $729M, Enabling Technologies $34.9M. Operating margin 23.2%, net earnings $141M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $763.7M in Q3 2026, down 1% year over year and down 3% from the previous quarter. Musculoskeletal Solutions was the largest line at 95% of revenue. Musculoskeletal Solutions lost $12.2M year over year (down 2%), 228% of the total change.
Operating profit was $177.6M, a 23.2% margin (up 5.4 points year over year). Total costs fell 7% while revenue fell 1%. The fastest-growing cost line was Other operating costs (+10%). Net earnings were $141.2M, up 19% year over year. The effective tax rate was 23.0%.
Operating cash flow was $265.2M (up 6% year over year), 188% of net earnings. Non-cash charges added back $70.4M of depreciation and amortization and $11.7M of share-based compensation. Working capital and other items added $41.9M. After purchases of property and equipment ($40.4M), free cash flow as the company reports it was $224.8M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $764M | -0.7% | 23.2% | $141M | $265M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $790M | +6% | 23.1% | $152M | $210M |
| Q1 2026 | 10-Q | May 7, 2026 | $760M | +27% | 19.8% | $124M | $202M |
| Q4 2025 | 10-K | Feb 24, 2026 | $826M | +26% | 20.5% | $141M | $249M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $769M | +23% | 17.9% | $119M | $250M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $745M | +18% | 10.2% | $203M | $77.9M |
| Q1 2025 | 10-Q | May 8, 2025 | $598M | -1% | 16.2% | $75.5M | $177M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Globus Medical
Globus Medical, Inc. (together, as applicable, with its consolidated subsidiaries, “Globus,” the “Company,” “we,” “us” or “our”), headquartered in Audubon, Pennsylvania, is a medical device company that develops and commercializes healthcare solutions whose mission is to improve the quality of life of patients with musculoskeletal disorders. Founded in 2003, Globus is committed to medical device innovation and delivering exceptional service to hospitals, ambulatory surgery centers and physicians to advance patient care and improve efficiency. Since inception, Globus has listened to the voice of the surgeon to develop practical solutions and products to help surgeons effectively treat patients and improve lives.
In its own words, from its 10-K, filed Feb 24, 2026.
Globus Medical against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -0.7% against the peers' median +5%. Operating margin: 23.2% against the peers' median 15.9%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| GMED Globus Medical | Q3 2026 | $764M | -0.7% | 23.2% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Globus Medical 10-Q on SEC EDGAR · CIK 1237831 · Surgical & Medical Instruments & Apparatus
Guidance and outlook
13F: who owns GMED and who is buying
More on GMED
- How Globus Medical makes money: revenue by segment
- Globus Medical next earnings date and what analysts expect
- Globus Medical stock forecast, price target and fair value
- Who owns Globus Medical stock: holders, funds and Congress trades
- Globus Medical guidance and outlook
- Is Globus Medical a takeover target? LBO and rumors
- Globus Medical recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- Globus Medical guidance history: guided vs reported
- Globus Medical operating margin by quarter
- Globus Medical net income by quarter
- Globus Medical free cash flow by quarter
- Globus Medical R&D spending by quarter
- Globus Medical capital expenditures by quarter
- Globus Medical Musculoskeletal Solutions revenue by quarter
- Globus Medical Enabling Technologies revenue by quarter